drugset
drugset / Trial / NCT00973388

VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

NCT00973388 ↗

Phase 1 Completed 44 enrolled Tibotec BVBA Vertex Pharmaceuticals Incorporated · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect of telaprevir on the results of electrocardiograms in healthy volunteers. An electrocardiogram is an electric recording of the heart. Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection.

Timeline

Start
2009-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Telaprevir Small molecule 750 mg Oral
Subject Telaprevir Small molecule 1875 mg Oral

Indications

hepatitis C virus infection